News und Analysen

I don't like the term "growth stock" all that much. Investors want their money to grow in some shape, form, or fashion with every stock they buy. However, I understand that textbook growth stocks

Schwartz Investment Counsel disclosed that it reduced its position in Chemed Corporation (NYSE:CHE) by 28,771 shares during the quarter, according to a 13F form filed with the Securities and

Intellia Therapeutics (NASDAQ: NTLA), a small-cap biotech company, has some notable bulls. One of them is Cathie Wood, the CEO of Ark Invest. The innovation-focused investment firm has long held

Viking Therapeutics (NASDAQ: VKTX) leaped onto center stage early last year when it announced promising news about a candidate addressing an area of soaring demand: weight loss. The biotech then

Dividends are one of investors' most powerful tools for earning strong returns over the long run. Buying shares of strong dividend-paying companies and reinvesting the payout allows compounding to

Buying dividend stocks at low prices can have two positive benefits. The first is that if you're buying low, the yield can be higher than normal. It can provide you with some high dividend income

A few years ago, Pfizer (NYSE: PFE) represented the ideal pharmaceutical stock investment. The company, as leader in the coronavirus vaccine and treatment market, offered a great deal of growth, and

AbbVie's (NYSE: ABBV) products are regularly used to help heal the sick, but the company's stock wasn't healthy for portfolios on Friday. The company published its latest quarterly earnings release

Shares of diabetes management equipment provider DexCom (NASDAQ: DXCM) had tumbled 17% by 11:15 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The culprit was the

Shares in Avidity Biosciences (NASDAQ: RNA) soared by 42% in the week to Friday morning following the announcement of a unanimous deal for Avidity to be acquired by Novartis (NYSE: NVS) for $72 per

It can take a while for growth stocks to reach their full potential, which is why they can make for good long-term options to hang on to. Along the way, however, they can encounter difficulties that

Glaukos (NYSE: GKOS), a biotech and pharmaceutical company focused on eye disorders, was the focus of the right kind of investor attention on Thursday. Market players bid the company's stock up by

Healthcare tech company Omnicell (NASDAQ: OMCL) was quite the picture of health on Thursday, at least as far as its equity was concerned. An encouraging quarterly earnings report sent its shares

Shares in Indivior Plc (NASDAQ: INDV) were up by 15.5% at 1 p.m. ET today after management released an excellent set of third-quarter results, upgraded its full-year guidance, and served notice that

Fenimore Asset Management Inc. fully exited its position in Waters Corporation (NYSE:WAT), selling approximately $85.09 million in shares.

According to a Q3 2025 filing submitted to the U.S

On October 28, 2025, EULAV Asset Management reported selling 28,313 shares of Chemed (NYSE:CHE) in Q3 2025, an estimated $12.82 million trade based on the average price during Q3 2025.

According to

Shares of DexCom (NASDAQ: DXCM), a medical device specialist, have lagged the broader market so far in 2025, down 11% year to date. The diabetes-focused healthcare company has faced several legal

AST SpaceMobile (NASDAQ: ASTS) is on a mission to eliminate dead zones through direct-to-smartphone satellite technology. Its partnerships with telecom giants like AT&T and Vodafone and its massive

In today's video, I discuss recent updates affecting Qualcomm (NASDAQ: QCOM), Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and other artificial intelligence stocks. To learn more,

There are plenty of attractive stocks on the market. Some, though, have significantly underperformed their growth potential this year, making them attractive at their current levels.

This list